Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$33.78 - $63.75 $65.8 Million - $124 Million
-1,948,786 Reduced 82.3%
419,030 $14.2 Million
Q1 2024

May 15, 2024

SELL
$60.14 - $75.36 $17.7 Million - $22.1 Million
-293,691 Reduced 11.03%
2,367,816 $154 Million
Q4 2023

Feb 14, 2024

SELL
$42.85 - $69.5 $12.1 Million - $19.6 Million
-282,203 Reduced 9.59%
2,661,507 $182 Million
Q3 2023

Nov 14, 2023

SELL
$49.5 - $66.6 $4.19 Million - $5.64 Million
-84,700 Reduced 2.8%
2,943,710 $153 Million
Q2 2023

Aug 14, 2023

BUY
$48.54 - $61.64 $1.3 Million - $1.65 Million
26,748 Added 0.89%
3,028,410 $182 Million
Q1 2023

May 15, 2023

SELL
$46.12 - $65.71 $14.7 Million - $21 Million
-319,404 Reduced 9.62%
3,001,662 $148 Million
Q4 2022

Feb 14, 2023

SELL
$45.51 - $65.08 $7.86 Million - $11.2 Million
-172,677 Reduced 4.94%
3,321,066 $190 Million
Q3 2022

Nov 14, 2022

BUY
$37.34 - $57.44 $30.7 Million - $47.2 Million
822,091 Added 30.77%
3,493,743 $164 Million
Q2 2022

Aug 15, 2022

BUY
$25.46 - $37.72 $3.05 Million - $4.51 Million
119,618 Added 4.69%
2,671,652 $99.7 Million
Q1 2022

May 16, 2022

BUY
$18.94 - $34.29 $1.52 Million - $2.76 Million
80,479 Added 3.26%
2,552,034 $76.3 Million
Q4 2021

Feb 14, 2022

BUY
$27.58 - $40.0 $728,112 - $1.06 Million
26,400 Added 1.08%
2,471,555 $84.6 Million
Q3 2021

Nov 15, 2021

BUY
$27.98 - $40.0 $1.41 Million - $2.01 Million
50,370 Added 2.1%
2,445,155 $90.6 Million
Q2 2021

Aug 16, 2021

BUY
$32.22 - $41.5 $3.3 Million - $4.25 Million
102,500 Added 4.47%
2,394,785 $93.5 Million
Q1 2021

May 17, 2021

BUY
$36.3 - $56.34 $83.2 Million - $129 Million
2,292,285 New
2,292,285 $97.6 Million

Others Institutions Holding IMCR

About Immunocore Holdings plc


  • Ticker IMCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,897,100
  • Market Cap $1.24B
  • Description
  • Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...
More about IMCR
Track This Portfolio

Track Rock Springs Capital Management LP Portfolio

Follow Rock Springs Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rock Springs Capital Management LP with notifications on news.